U bent geen gezondheidszorgbeoefenaar? Bezoek onze publieke website.

Een mogelijke bijwerking melden

User logged in

Overlay Text

www.gskpro.com/nl-be

Voor gezondheidszorgbeoefenaars

Visit our Public site

Event Registration successful

You now have sucesfully register for the event and you can also access the latest updates, events and resources.

In case you would like to receive SMS-reminders for the event you have registered, please update your communication preferences here.

Account activated – pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

Event registration completed - pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We'll send you and email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.

Account activated - pending validation.

In the meantime, you can enjoy the public content on our website

Event Account activated - pending validation.

In the meantime, you can enjoy the public content on our website

In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.

already registered

X »

$previewUrl

Anoro Ellipta 20 mcg

has been lorem added to your basket

View Basket

Unit for Hours:H

Unit for Minutes: M

Filter redirection page URL: events.html

Filter Tags:Product|Therapeutische domeinen

Filter Tags values when filtered by all Tags:Alle producten | Alle therapiën | Alle indicaties

OutofBox filter category name:Formaat

Filter Reset all button text:Reset alles

Filter Apply button text:Toepassen

Events registration success message: U bent geregistreerd

Events registration failure message: U bent niet geregistreerd

Events un-registration success message: U bent uitgeschreven

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Tag Requirements value: all

Show More Naivagation Values: 10|25|50

Previous Text label: Vorige

Next Text label: Volgende

Show Text label: Toon:

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:$ciamTextareaNoCopyEmail

U klikt door naar een site van derden.

GSK aanvaardt betreffende het gebruik van websites in beheer door derden, inclusief hun inhoud, geen enkele verantwoordelijkheid.

Verder

Ga terug

EXDENSUR: More time between injections. More CONVENIENCE.

More injection-free days for patients with severe uncontrolled asthma characterized by Type 2 inflammation^a and/or severe uncontrolled CRSwNP with only 2 injections per year.¹

EXDENSUR (depemokimab) may support adherence through its pioneering dosing regimen and offers patients a new level of therapeutic freedom.¹

EXDENSUR: The First and Only Biologic for Severe Uncontrolled Asthma with Ultra-Long-Lasting Duration of Action^1-5

Give your patients more injection-free days with only 2 doses of EXDENSUR per year.¹

Only selected biologics are shown. No conclusions regarding comparative efficacy or safety can be drawn from this information.

EXDENSUR: The First and Only Ultra-Long-Acting Biologic for Severe Uncontrolled CRSwNP^1-3,5

Give your patients more injection-free days with only 2 doses of EXDENSUR per year.¹

Only selected biologics are shown. No conclusions regarding comparative efficacy or safety can be drawn from this information.

Available as a Prefilled Syringe and Prefilled Pen:

Go to SmPC

Abbreviations

CRSwNP = Chronic Rhinosinusitis with Nasal Polyps.

Footnotes

a Characterized by eosinophils.

b Asthma dosing interval: Dupilumab is routinely administered 26 times per year at two-week intervals; the initial dose at treatment initiation consists of two administrations (Year 1: 27 administrations in total)⁴

References
GlaxoSmithKline EXDENSUR (depemokimab). Summary of Product Characteristics (SmPC). 2026.

Fasenra (benralizumab). Summary of Product Characteristics (SmPC). 2026.

Tezpire (tezepelumab). Summary of Product Characteristics (SmPC). 2026.

Dupixent (dupilumab). Summary of Product Characteristics (SmPC). 2026.

GlaxoSmithKline NUCALA (mepolizumab). Summary of Product Characteristics (SmPC). 2026.

PM-BE-DEPE-WCNT-260010 - September 2026

Neem contact op

Contacteer ons

©2025-2028 GSK bedrijvengroep of zijn licentiegever. Handelsmerken zijn eigendom van of in licentie bij de GSK bedrijvengroep. Alle rechten voorbehouden. GlaxoSmithKline Pharmaceuticals s.a./n.v. Avenue Fleming 20, 1300 Waver België PM-BE-NA-WCNT-260001 (V2.0) - Mei. 2026

U klikt door naar een site van derden.

EXDENSUR: More time between injections. More CONVENIENCE.

Give your patients more injection-free days with only 2 doses of EXDENSUR per year.1

Give your patients more injection-free days with only 2 doses of EXDENSUR per year.1

Neem contact op

Give your patients more injection-free days with only 2 doses of EXDENSUR per year.¹

Give your patients more injection-free days with only 2 doses of EXDENSUR per year.¹